Pfizer Pipeline

As of January 31, 2017

Disclaimer

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of January 31, 2017.

- Visit Pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

Table of Contents

Pfizer Pipeline Snapshot



Pipeline represents progress of R&D programs as of January 31, 2017

Included are 62 NMEs, 26 additional indications, plus 8 biosimilars

3 projects discontinued since last update

Recent Approvals

- Eucrisa (crisaborole) for Atopic Dermatitis (US)
- Ibrance (palbociclib) for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer (EU)



Pipeline represents progress of R&D programs as of November 1, 2016

Included are 62 NMEs, 24 additional indications, plus 8 biosimilars

5 projects discontinued since last update

Recent Approvals

- Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) for Severe Pain (US)
- Xalkori (crizotinib) for ROS1+ Non-Small Cell Lung Cancer (EU)

New Molecular Entity

Pfizer Pipeline – January 31, 2017

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Cardiovascular and Metabolic Diseases	ertugliflozin (PF-04971729)	SGLT-2 Inhibitor	Diabetes Mellitus-Type 2	Phase 3
	PF-05221304		Non-Alcoholic Steatohepatitis (NASH)	Phase 1
	PF-06282999		Acute Coronary Syndrome	Phase 1
	PF-06293620		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
	PF-06427878		Hyperlipidemia	Phase 1
	▶ PF-06835919		Non-Alcoholic Steatohepatitis (NASH)	Phase 1

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

Pfizer Pipeline – January 31, 2017 (cont'd)

New Molecular Entity

New Indication or Enhancement

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Inflammation and Immunology	Xeljanz (tofacitinib)	JAK Inhibitor	RA (E.U.)	Registration
	Xeljanz (tofacitinib)	JAK Inhibitor	Ulcerative Colitis	Phase 3
	Xeljanz (tofacitinib)	JAK Inhibitor	Psoriatic Arthritis	Phase 3
	Dekavil	IL-10	Rheumatoid Arthritis, *Inflammatory Bowel Disease (Biologic)	Phase 2
	PF-04965842	JAK Inhibitor	Atopic Dermatitis	Phase 2
	PF-06480605	TNFSF15 Blocker	Ulcerative Colitis (Biologic)	Phase 2
	▶ PF-06650833	IRAK4	Rheumatoid Arthritis	Phase 2
	▶ PF-06651600	JAK3	Rheumatoid Arthritis, Alopecia Areata	Phase 2
	▶ PF-06700841	TYK2/JAK1	Psoriasis, Alopecia Areata	Phase 2
	PF-06342674		Diabetes Mellitus-Type 1-(Biologic)	Phase 1
	PF-06423264		Acne	Phase 1
	PF-06817024		Atopic Dermatitis (Biologic)	Phase 1
	PF-06823859		Lupus (Biologic)	Phase 1

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1

Pfizer Pipeline – January 31, 2017 (cont'd)

New Molecular Entity

New Indication or Enhancement

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Neuroscience and Pain	Lyrica	Alpha-2 Delta Ligand	CR (once a day dosing)	Phase 3
	tanezumab	Nerve Growth Factor Inhibitor	OA Signs and Symptoms, Chronic Low Back Pain, Cancer Pain (Biologic)	Phase 3
	PF-02545920	PDE10 Inhibitor	Huntington's Disease **(ORPHAN - U.S.)**	Phase 2
	PF-06372865	GABA A Receptor Agonist	Epilepsy	Phase 2
	PF-06649751	Modulator of Dopamine Signaling	Parkinson's Disease	Phase 2
	PF-04958242		Schizophrenia	Phase 1
	PF-05251749		Alzheimer's Disease	Phase 1
	PF-06648671		Alzheimer's Disease	Phase 1
	PF-06669571		Cognitive Disorder	Phase 1
	PF-06751979		Alzheimer's Disease	Phase 1
	▶ PF-06818883		Intracerebral Hemorrhage	Phase 1

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

Indicates Regulatory Designation – See Definitions in Backup

Pfizer Pipeline – January 31, 2017 (cont'd)

New Molecular Entity

New Indication or Enhancement

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Oncology (1 of 3)	►avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	2nd Line Metastatic Merkel Cell Carcinoma **(BREAKTHROUGH, FAST TRACK, ORPHAN, PRIORITY REVIEW - U.S.)** (Biologic)	Registration
	inotuzumab ozogamicin	CD22-targeted cytotoxic agent	Acute Lymphoblastic Leukemia (E.U.) (Biologic) **(ORPHAN - E.U.)**	Registration
	►Mylotarg	CD33-targeted cytotoxic agent	1st Line Acute Myeloid Leukemia (Biologic)	Registration
	avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	2nd Line Non-Small Cell Lung Cancer (Biologic)	Phase 3
	avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	1st Line Non-Small Cell Lung Cancer (Biologic)	Phase 3
	avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	1st Line Gastric Cancer (Biologic)	Phase 3
	avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	3rd Line Gastric Cancer (Biologic)	Phase 3
	avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	Platinum Resistant/Refractory Ovarian Cancer (Biologic)	Phase 3
	avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	1st Line Ovarian Cancer (Biologic)	Phase 3
	avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	1st Line Urothelial Cancer (Biologic)	Phase 3
	avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib))	Phase 3
	►avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic)	Phase 3
	Bosulif (bosutinib)	Abl and src-family Kinase Inhibitor	1st Line Chronic Myelogenous Leukemia **(ORPHAN - U.S.)**	Phase 3
	dacomitinib (PF-00299804)	pan-HER Inhibitor	1st Line EGFR mutant Non-Small Cell Lung Cancer **(ORPHAN - U.S.)**	Phase 3

►Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

Indicates Regulatory Designation – See Definitions in Backup

Pfizer Pipeline – January 31, 2017 (cont'd)

New Molecular Entity

New Indication or Enhancement

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Oncology (2 of 3)	Ibrance (palbociclib)	CDK 4,6 Kinase Inhibitor	High Risk Early Breast Cancer	Phase 3
	Ibrance (palbociclib)	CDK 4,6 Kinase Inhibitor	Early Breast Cancer in Adjuvant Setting, *Cancer	Phase 3
	Inlyta (axitinib)	VEGF Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant, *Cancer combo w/ Merck's Keytruda (PD-1, pembrolizumab), *Combo w/ Xalkori for RCC	Phase 3
	inotuzumab ozogamicin	CD22-targeted cytotoxic agent	Acute Lymphoblastic Leukemia (U.S.) (Biologic) **(BREAKTHROUGH, ORPHAN - U.S.)**	Phase 3
	Sutent (sunitinib)	Multiple Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant	Phase 3
	talazoparib (MDV3800)	PARP inhibitor	Germline BRCA Mutated Metastatic Breast Cancer	Phase 3
	Xtandi (enzalutamide)	Androgen receptor inhibitor	Metastatic Hormone Sensitive Prostate Cancer	Phase 3
	Xtandi (enzalutamide)	Androgen receptor inhibitor	Non-metastatic Castrate Resistant Prostate Cancer	Phase 3
	Xtandi (enzalutamide)	Androgen receptor inhibitor	Non-metastatic High Risk Hormone Sensitive Prostate Cancer	Phase 3
	Xtandi (enzalutamide)	Androgen receptor inhibitor	Triple Negative Breast Cancer	Phase 3
	avelumab (PF-06834635) (MSB0010718C)	Anti PD-L1 Inhibitor	1st Line Merkel Cell Carcinoma, *Cancer, Combo w/ PF-05082566 (41BB) for: Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Melanoma (Biologic)	Phase 2
	glasdegib (PF-04449913)	SMO (smoothened) antagonist	Acute Myeloid Leukemia, *Cancer	Phase 2
	Ibrance (palbociclib)	CDK 4,6 Kinase Inhibitor	Squamous Cell Carcinoma of the Head and Neck	Phase 2

Indicates Regulatory Designation – See Definitions in Backup

* Note: Additional indications in Phase 1

Pfizer Pipeline – January 31, 2017 (cont'd)

New Molecular Entity

New Indication or Enhancement

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Oncology (3 of 3)	lorlatinib (PF-06463922)	ALK Inhibitor	ALK Non-Small Cell Lung Cancer **(ORPHAN - U.S.)**	Phase 2
	Xtandi (enzalutamide)	Androgen receptor inhibitor	ER/PR+ & HER2 normal Breast Cancer; AR+, HER2+ amplified Breast Cancer; Hepatocellular Carcinoma	Phase 2
	gedatolisib (PF-05212384)		Cancer	Phase 1
	PF-04136309		Pancreatic Cancer	Phase 1
	PF-04518600		Cancer, Combo w/ avelumab (PD-L1) (Biologic)	Phase 1
	PF-05082566		Cancer (Biologic), Combo w/ Merck's Keytruda (PD-1, pembrolizumab), Combo w/ Kyowa Hakko Kirin's anti-CCR4 antibody (mogamulizumab)	Phase 1
	PF-06647020		Cancer (Biologic)	Phase 1
	PF-06647263		Cancer (Biologic)	Phase 1
	PF-06671008		Cancer (Biologic)	Phase 1
	► PF-06747143		Acute Myeloid Leukemia (Biologic)	Phase 1
	PF-06747775		Cancer	Phase 1
	PF-06801591		Cancer Immunotherapy (Biologic)	Phase 1
	PF-06840003		Cancer	Phase 1
	PF-06883541		Cancer (Biologic)	Phase 1

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

Indicates Regulatory Designation – See Definitions in Backup

Pfizer Pipeline – January 31, 2017 (cont'd)

New Molecular Entity

New Indication or Enhancement

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Rare Diseases	tafamidis meglumine	Transthyretin (TTR) Dissociation Inhibitor	Transthyretin familial amyloid polyneuropathy (U.S.) **(FAST TRACK, ORPHAN - U.S.)**	Registration
	PF-06836922 (MOD-4023)	Human Growth Hormone Agonist	Adult Growth Hormone Deficiency (Biologic) **(ORPHAN - U.S., E.U.)**	Phase 3
	rivipansel (GMI-1070)	Pan-Selectin Antagonist	Vaso-occlusive crisis associated with Sickle Cell Disease **(FAST TRACK, ORPHAN - U.S., E.U.)**	Phase 3
	Vyndaqel (tafamidis meglumine)	Transthyretin (TTR) Dissociation Inhibitor	Adult Symptomatic Transthyretin Cardiomyopathy **(ORPHAN - U.S., E.U. **)**	Phase 3
	PF-06252616	Myostatin Inhibitor	Duchenne Muscular Dystrophy (Biologic) **(FAST TRACK, ORPHAN - U.S., E.U.)**	Phase 2
	PF-06836922 (MOD-4023)	Human Growth Hormone Agonist	Pediatric Growth Hormone Deficiency (Biologic) **(ORPHAN - U.S., E.U.)**	Phase 2
	PF-06838435	Gene Therapy, coagulation factor IX (F9)	Hemophilia (Biologic) **(BREAKTHROUGH, ORPHAN - U.S.)**	Phase 2
	PF-04447943		Sickle Cell Anemia **(ORPHAN - U.S.)**	Phase 1
	PF-05230907		Intracerebral Hemorrhage (Biologic) **(ORPHAN - U.S.)**	Phase 1
	PF-06741086		Hemophilia (Biologic) **(ORPHAN - U.S., E.U.)**	Phase 1

Indicates Regulatory Designation – See Definitions in Backup

** Note: Two EU orphan designations apply to Vyndaqel in cardiomyopathy: One for patients with familial amyloid cardiomyopathy due to a genetic variant of the TTR gene(TTR-FAC), and another EU orphan designation for senile systemic amyloidosis, for cardiomyopathy in patients without the gene variant (TTR-Wild Type).

New Molecular Entity

Pfizer Pipeline – January 31, 2017 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Vaccines	Trumenba (MnB rLP2086)	Prophylactic Vaccine	Adolescent and Young Adult Meningitis B (E.U.)	Registration
	4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510)	Prophylactic Vaccine	Staph aureus **(FAST TRACK)**	Phase 2
	PF-06425090	Prophylactic Vaccine	Clostridium difficile Colitis **(FAST TRACK)**	Phase 2
	► PF-06482077		Bacterial Infections	Phase 1
	PF-06753512		Prostate Cancer	Phase 1

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

Indicates Regulatory Designation – See Definitions in Backup

Pfizer Pipeline – January 31, 2017 (cont'd)

New Molecular Entity

Biosimilar

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Other Areas of Focus (Biosimilars)	Retacrit®, a potential biosimilar to Epogen® and Procrit® (epotein alfa)	Erythropoietin	Treatment of Anemia (Biosimilar)	Registration
	PF-05280014, a potential biosimilar to Herceptin® (trastuzumab)	erbB2 TK Inhibitor	Metastatic Breast Cancer (Biosimilar)	Phase 3
	PF-05280586, a potential biosimilar to Rituxan® /MabThera (rituximab)	CD20 Antigen Antagonist	Follicular Lymphoma (Biosimilar)	Phase 3
	PF-06410293, a potential biosimilar to Humira® (adalimumab)	Tumor Necrosis Factor Inhibitor	Rheumatoid Arthritis (Biosimilar)	Phase 3
	PF-06438179, a potential biosimilar to Remicade® (infliximab)	Tumor Necrosis Factor Inhibitor	Rheumatoid Arthritis (ex-European Economic Area) (Biosimilar)	Phase 3
	PF-06439535, a potential biosimilar to Avastin® (bevacizumab)	VEGF inhibitor	Non-Small Cell Lung Cancer (Biosimilar)	Phase 3
	Filgrastim, a potential biosimilar to Neupogen® (filgrastim)		Neutropenia in patients undergoing cancer chemotherapy (Biosimilar)	Phase 1
	HSP-130, a potential biosimilar to Neulasta® (Pegfilgrastim)		Neutropenia in patients undergoing cancer chemotherapy (Biosimilar)	Phase 1
Other Areas of Focus	► aztreonam-avibactam (PF-06947387)	Beta Lactam/Beta Lactamase Inhibitor	Complicated Urinary Tract Infections, Hospital-Acquired Pneumonia/Ventilator-Acquired Pneumonia	Phase 2
	PF-05206388		Age-Related Macular Degeneration (Exudative wet) (Biologic)	Phase 1

Remicade® is a registered U.S. trademark of Janssen Biotech, Inc.; Rituxan® is a registered U.S. trademark of Biogen MA Inc.; MabThera is a trademark of F. Hoffmann La Roche AG; Avastin® and Herceptin® are registered U.S. trademarks of Genentech, Inc.; Humira® is a registered U.S. trademark of Abbvie Biotechnology Ltd.; Retacrit® is a registered U.S. trademark of Hospira, Inc.; Epogen®, Neupogen® and Neulasta® are registered U.S. trademarks of Amgen Inc.; Procrit® is a registered U.S. trademark of Johnson & Johnson

► Indicates that the project is either new or` has progressed in phase since the previous portfolio update of Pfizer.com

Projects Discontinued from Development since November 1, 2016

New Molecular Entity

Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
PF-06291874	Glucagon Receptor Antagonist	Diabetes Mellitus-Type 2	Phase 2
PF-06412562		Cognitive Disorder	Phase 1
PF-06815345		Hyperlipidemia	Phase 1

Backup

Regulatory Designation Definitions

- ***Fast Track*** (U.S.) is a designation available to a product if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. This designation is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. More information about the qualifying criteria and features of the Fast Track program can be found on the FDA's website.
- ***Breakthrough Designation*** (U.S.) may be granted to a drug (alone or in combination with 1 or more other drugs) intended to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A drug that receives breakthrough designation is eligible for all fast track designation features and an FDA commitment to work closely with the sponsor to ensure an efficient drug development program. More information about the qualifying criteria and features of the Breakthrough program can be found on the FDA's website.
- ***Orphan Drug (US)*** - Orphan drug status may be granted to drugs and biologics that are intended for the diagnosis, prevention, or treatment of rare diseases/disorders that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but where it is unlikely that expected sales of the product would cover the sponsor's investment in its development. More information about the qualifying criteria, features, and incentives involved in an orphan drug designation can be found on the FDA's website.
- ***Orphan Drug (Europe)*** - Orphan drug status may be granted to drugs and biologics that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than 5 in 10,000 persons in the European Union at the time of submission of the designation application, or that affect more than 5 in 10,000 persons but where it is unlikely that expected sales of the product would cover the investment in its development. More information about the qualifying criteria, features, and incentives involved in an orphan drug designation can be found on the EMA's website.
- A U.S. drug application will receive a ***priority review designation*** if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. A priority designation is intended to direct overall attention and resources to the evaluation of such applications. A priority review designation means that FDA's goal is to take action on the marketing application within 6 months of receipt (compared with 10 months under standard review). More information about the qualifying criteria and features of a priority review designation can be found on the FDA's website.
- ***PRIME*** (E.U.) **-** The PRIME scheme is applicable to products under development which are innovative and yet to be placed on the EU market. The scheme aims to support medicinal products of major public health interest and in particular from the viewpoint of therapeutic innovation. Medicines eligible for PRIME must address an unmet medical need, i.e. for which there exists no satisfactory method of diagnosis, prevention or treatment in the Community or, if such a method exists, in relation to which the medicinal product concerned will be of major therapeutic advantage to those affected. A product eligible for PRIME should demonstrate the potential to address, to a significant extent, the unmet medical need, for example by introducing new methods of therapy or improving existing ones. Data available to support the request for eligibility should support the claim to address the unmet medical need through a clinically meaningful improvement of efficacy, such as having a clinically meaningful improvement of efficacy, such as having an impact on the prevention, onset or duration of the condition, or improving the morbidity or mortality of the disease. EMA will provide early and enhanced support to optimize the development of eligible medicines. Products granted PRIME support are anticipated to benefit from the Accelerated Assessment procedure. More information about the qualifying criteria and features of PRIME and Accelerated Assessment can be found on the EMA's website.